{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:37:30Z","timestamp":1781066250164,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012469","name":"O'Brien Institute for Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000001","name":"Alberta Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jtct.2022.10.013","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T13:57:50Z","timestamp":1666274270000},"page":"43.e1-43.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Rituximab Toxicity after Preemptive or Therapeutic Administration for Post-Transplant Lymphoproliferative Disorder"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2139-5174","authenticated-orcid":false,"given":"Megan","family":"Kinzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4269-7622","authenticated-orcid":false,"given":"Rutvij A.","family":"Khanolkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5029-2345","authenticated-orcid":false,"given":"Tyler S.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-6598","authenticated-orcid":false,"given":"Robert","family":"Puckrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Shafey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7884-9122","authenticated-orcid":false,"given":"Jan","family":"Storek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.10.013_bib0001","doi-asserted-by":"crossref","first-page":"53.e1","DOI":"10.1016\/j.jtct.2021.09.021","article-title":"Risk factors for the incidence and the mortality due to post-transplant lymphoproliferative disorder after hematopoietic cell transplantation","volume":"28","author":"Kinzel","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.10.013_bib0002","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3324\/haematol.2013.087338","article-title":"Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation","volume":"99","author":"Uhlin","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.10.013_bib0003","first-page":"1059","article-title":"The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation","volume":"91","author":"Sundin","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.10.013_bib0004","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bmt.2013.84","article-title":"Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab","volume":"48","author":"van der Velden","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0005","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/cid\/cit391","volume":"57","author":"Styczynski","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2022.10.013_bib0006","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.bbmt.2019.02.016","article-title":"Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation","volume":"25","author":"Fujimoto","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0007","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.013_bib0008","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/bmt.2013.190","article-title":"EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases","volume":"49","author":"Sanz","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0009","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00277-019-03742-7","article-title":"Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies","volume":"98","author":"Gao","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.10.013_bib0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/bmt.2013.96","article-title":"EBV-induced post-transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoietic SCT","volume":"49","author":"Rasche","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0011","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13150","article-title":"Risk factors for post-transplant lymphoproliferative disorder after thymoglobulin-conditioned hematopoietic cell transplantation","volume":"32","author":"Kalra","year":"2018","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0012","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/00365540600978906","article-title":"Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction","volume":"39","author":"Kinch","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jtct.2022.10.013_bib0013","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood.V98.4.972","article-title":"Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT","volume":"98","author":"van Esser","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.013_bib0014","first-page":"2208","article-title":"Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study","volume":"94","author":"Curtis","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.013_bib0015","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.10.013_bib0016","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1182\/blood.V99.12.4364","article-title":"Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation","volume":"99","author":"van Esser","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.013_bib0017","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbmt.2009.10.008","article-title":"Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation","volume":"16","author":"Blaes","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-6143.2009.02785.x","article-title":"Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients","volume":"10","author":"Kamar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0019","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41409-019-0699-6","article-title":"Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes","volume":"55","author":"Stocker","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0020","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/TP.0b013e3182664042","article-title":"Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation","volume":"94","author":"Petropoulou","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2022.10.013_bib0021","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.bbmt.2010.05.004","article-title":"Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias","volume":"16","author":"McIver","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0022","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bmt.1704742","article-title":"Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia","volume":"35","author":"Lim","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 2","key":"10.1016\/j.jtct.2022.10.013_bib0023","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jtct.2022.10.013_bib0024","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12032-008-9049-z","article-title":"Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis","volume":"25","author":"Tesfa","year":"2008","journal-title":"Med Oncol"},{"key":"10.1016\/j.jtct.2022.10.013_bib0025","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.bbmt.2009.11.017","article-title":"The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia","volume":"16","author":"Russell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0026","doi-asserted-by":"crossref","first-page":"e14018","DOI":"10.1111\/ctr.14018","article-title":"Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin","volume":"34","author":"Ousia","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0027","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0028","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0029","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/bloodadvances.2016000836","article-title":"Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir\/valacyclovir followed by vaccination","volume":"1","author":"Jamani","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.10.013_bib0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcyt.2019.11.002","article-title":"High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era","volume":"22","author":"Evernden","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2022.10.013_bib0031","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.bbmt.2016.05.020","article-title":"Impact of donor and recipient cytomegalovirus serostatus on outcomes of antithymocyte globulin-conditioned hematopoietic cell transplantation","volume":"22","author":"Kalra","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0032","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbmt.2015.09.003","article-title":"Low counts of B cells, natural killer cells, monocytes, dendritic cells, basophils, and eosinophils are associated with postengraftment infections after allogeneic hematopoietic cell transplantation","volume":"22","author":"Podgorny","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0033","doi-asserted-by":"crossref","first-page":"e13095","DOI":"10.1111\/tid.13095","article-title":"Epidemiology of viral infections among children undergoing hematopoietic stem cell transplant: a prospective single-center study","volume":"21","author":"Tsoumakas","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2022.10.013_bib0034","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jcyt.2018.02.367","article-title":"Epstein-Barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder","volume":"20","author":"Kalra","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2022.10.013_bib0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/tid.12061","article-title":"Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab","volume":"15","author":"Patriarca","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2022.10.013_bib0036","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5500\/wjt.v10.i2.29","article-title":"Post-transplantation lymphoproliferative disorders: current concepts and future therapeutic approaches","volume":"10","author":"Abbas","year":"2020","journal-title":"World J Transplant"},{"key":"10.1016\/j.jtct.2022.10.013_bib0037","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/bloodadvances.2021004629","article-title":"Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients","volume":"5","author":"Vijenthira","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.10.013_bib0038","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13045-021-01190-3","article-title":"Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients","volume":"14","author":"Canti","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.10.013_bib0039","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jtct.2021.01.017","article-title":"An immune recovery-based revaccination protocol for pediatric hematopoietic stem cell transplant recipients: revaccination outcomes following pediatric HSCT","volume":"27","author":"Haynes","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.10.013_bib0040","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722017079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722017079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:08:08Z","timestamp":1763003288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722017079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2666636722017079"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.10.013","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab Toxicity after Preemptive or Therapeutic Administration for Post-Transplant Lymphoproliferative Disorder","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}